PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Testosterone

Drugs in development · updated 30 October 2026

Testosterone: clinical trials and development status

Other names and codes: Natesto, Vogelxo, Axiron, Androgel

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 28 July 2006

As of 30 October 2026 Testosterone is in 12 active clinical trials (recruiting or ongoing, phases I–III) for 14 diseases. The most advanced phase is III.

12Active trials
IIIMost advanced phase
14Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Testosterone and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
HypogonadismIII3NCT04833426
Prostatic NeoplasmsIII3NCT04833426
DyspareuniaII–III1NCT07260825
Gender dysphoriaIII1NCT06351501
InfertilityIII1NCT05586802
Klinefelter's syndromeIII1NCT05586802
Metabolic syndromeIII1NCT05586802
Vulvar Lichen SclerosusII–III1NCT07260825
VulvodyniaII–III1NCT07260825
EunuchismII2NCT04301765
FatigueII1NCT04301765
Intraductal carcinoma of the breastII1NCT06075953
NeoplasmII1NCT04301765
Postmenopausal osteoporosisII1NCT07254429

Everything on Testosterone

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch